Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taiwan TCMs Set To Hit Mainland Market

This article was originally published in PharmAsia News

Executive Summary

At a recent forum on cross-strait TCM cooperation and technology exchange, Xiamen Traditional Chinese Medicine signed a letter of intent for TCM industry collaboration with Taiwan's three pharmaceutical companies - Sun Ten Pharmaceutical, Sheng Chang Pharmaceutical and Chuang Song Zong Pharmaceutical. The China firm promises to use its marketing channels to bring Taiwan-made health products and TCM into the mainland market. In addition, Taiwan and China will leverage on Xiamen as a platform for TCM communication and will enhance cooperation on raw material purchases, herbal slice processing, herbal extract production, TCM formulation innovation, new drug development and establishing marketing channels. Both parties also reached an understanding on codeveloping TCM business opportunities in a global market. (Click here for more - Chinese Language)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067495

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel